Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized, controlled, double-blind,...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Zafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Busra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mumtaz Mazicioglu, Gamze Kalin Unuvar, Zeynep Ture Yuce, Gunsu Aydin, Refika Kamuran Kaya, Ihsan Ates, Ates Kara, Aykut Ozdarendeli
Materialtyp: Artikel
Språk:English
Publicerad: MDPI AG 2024-01-01
Serie:Vaccines
Ämnen:
booster
COVID-19
immunogenicity
inactivated vaccine
neutralizing antibody
S1 RBD
Länkar:https://www.mdpi.com/2076-393X/12/2/140

Internet

https://www.mdpi.com/2076-393X/12/2/140

Liknande verk